205 related articles for article (PubMed ID: 35858562)
1. FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Simpson AP; Roghanian A; Oldham RJ; Chan HTC; Penfold CA; Kim HJ; Inzhelevskaya T; Mockridge CI; Cox KL; Bogdanov YD; James S; Tutt AL; Rycroft D; Morley P; Dahal LN; Teige I; Frendeus B; Beers SA; Cragg MS
Cell Rep; 2022 Jul; 40(3):111099. PubMed ID: 35858562
[TBL] [Abstract][Full Text] [Related]
2. Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.
Vaughan AT; Chan CH; Klein C; Glennie MJ; Beers SA; Cragg MS
J Biol Chem; 2015 Feb; 290(9):5424-37. PubMed ID: 25568316
[TBL] [Abstract][Full Text] [Related]
3. FcγRIIB as a key determinant of agonistic antibody efficacy.
White AL; Beers SA; Cragg MS
Curr Top Microbiol Immunol; 2014; 382():355-72. PubMed ID: 25116108
[TBL] [Abstract][Full Text] [Related]
4. Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection.
Boonnak K; Slike BM; Donofrio GC; Marovich MA
J Immunol; 2013 Jun; 190(11):5659-65. PubMed ID: 23616574
[TBL] [Abstract][Full Text] [Related]
5. HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Hussain K; Liu R; Smith RCG; Müller KTJ; Ghorbani M; Macari S; Cleary KLS; Oldham RJ; Foxall RB; James S; Booth SG; Murray T; Dahal LN; Hargreaves CE; Kemp RS; Longley J; Douglas J; Markham H; Chee SJ; Stopforth RJ; Roghanian A; Carter MJ; Ottensmeier CH; Frendéus B; Cutress RI; French RR; Glennie MJ; Strefford JC; Thirdborough SM; Beers SA; Cragg MS
J Exp Clin Cancer Res; 2022 Apr; 41(1):131. PubMed ID: 35392965
[TBL] [Abstract][Full Text] [Related]
6. Testing the role of the FcγRIIB immunoreceptor tyrosine-based inhibitory motif in regulation of the B cell immune response.
Vuyyuru R; Shen S; Manser T
Immun Inflamm Dis; 2015 Sep; 3(3):247-64. PubMed ID: 26417440
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
[TBL] [Abstract][Full Text] [Related]
8. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
9. Preclinical in vitro evaluation of immune suppression induced by GYM329, Fc-engineered sweeping antibody.
Iwata Y; Katada H; Okuda M; Doi Y; Ching TJ; Harada A; Takeiri A; Honda M; Mishima M
J Toxicol Sci; 2023; 48(7):399-409. PubMed ID: 37394653
[TBL] [Abstract][Full Text] [Related]
10. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
11. Functional regulation of human neutrophil Fc gamma receptors.
Selvaraj P; Fifadara N; Nagarajan S; Cimino A; Wang G
Immunol Res; 2004; 29(1-3):219-30. PubMed ID: 15181284
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SM201, an anti-hFcγRIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells.
Rieth N; Carle A; Müller MA; ter Meer D; Direnberger C; Pohl T; Sondermann P
Immunol Lett; 2014 Aug; 160(2):145-50. PubMed ID: 24472604
[TBL] [Abstract][Full Text] [Related]
13. Anti-FcγRIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcγRIII.
Clay CD; Strait RT; Mahler A; Khodoun MV; Finkelman FD
J Allergy Clin Immunol; 2018 Apr; 141(4):1373-1381.e5. PubMed ID: 28624610
[TBL] [Abstract][Full Text] [Related]
14. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Williams EL; Tutt AL; French RR; Chan HT; Lau B; Penfold CA; Mockridge CI; Roghanian A; Cox KL; Verbeek JS; Glennie MJ; Cragg MS
Eur J Immunol; 2012 Aug; 42(8):2109-20. PubMed ID: 22760702
[TBL] [Abstract][Full Text] [Related]
15. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA.
Huang ZY; Hunter S; Kim MK; Indik ZK; Schreiber AD
J Leukoc Biol; 2003 Jun; 73(6):823-9. PubMed ID: 12773515
[TBL] [Abstract][Full Text] [Related]
16. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas F; Furness AJS; Solomon I; Joshi K; Mekkaoui L; Lesko MH; Miranda Rota E; Dahan R; Georgiou A; Sledzinska A; Ben Aissa A; Franz D; Werner Sunderland M; Wong YNS; Henry JY; O'Brien T; Nicol D; Challacombe B; Beers SA; ; ; ; Turajlic S; Gore M; Larkin J; Swanton C; Chester KA; Pule M; Ravetch JV; Marafioti T; Peggs KS; Quezada SA
Immunity; 2017 Apr; 46(4):577-586. PubMed ID: 28410988
[TBL] [Abstract][Full Text] [Related]
17. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.
Chenoweth AM; Wines BD; Anania JC; Mark Hogarth P
Immunol Cell Biol; 2020 Apr; 98(4):287-304. PubMed ID: 32157732
[TBL] [Abstract][Full Text] [Related]
18. New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B).
Roghanian A; Stopforth RJ; Dahal LN; Cragg MS
J Leukoc Biol; 2018 Feb; ():. PubMed ID: 29406570
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Clynes RA; Towers TL; Presta LG; Ravetch JV
Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Roghanian A; Teige I; Mårtensson L; Cox KL; Kovacek M; Ljungars A; Mattson J; Sundberg A; Vaughan AT; Shah V; Smyth NR; Sheth B; Chan HT; Li ZC; Williams EL; Manfredi G; Oldham RJ; Mockridge CI; James SA; Dahal LN; Hussain K; Nilsson B; Verbeek JS; Juliusson G; Hansson M; Jerkeman M; Johnson PW; Davies A; Beers SA; Glennie MJ; Frendéus B; Cragg MS
Cancer Cell; 2015 Apr; 27(4):473-88. PubMed ID: 25873171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
